Overview

An Open-label Study of GC012F in Rheumatoid Arthritis.

Status:
NOT_YET_RECRUITING
Trial end date:
2041-01-15
Target enrollment:
Participant gender:
Summary
This is An Open-label Study to Evaluate the Safety and Efficacy of GC012F in Patients with Difficult-to-Treat (D2T) Rheumatoid Arthritis.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Treatments:
Cyclophosphamide
fludarabine